Notícias Kymera Therapeutics Inc - KYMR | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (KYMR) Notícias

Kymera Therapeutics Inc (KYMR)

38,19

-0,30

( -0,78% )

Atualizado: 15:02:41

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

Kymera Therapeutics Announces Proposed Public Offering

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Kymera Therapeutics

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições